TENON MEDICAL INC (TNON)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.72-1.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put TNON beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Sustain revenue growth near $1.47 million quarterly: rev $1.3M vs $1.47M target.
View ThesisRevenue growth is accelerating — up about 80% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 92% in its worst 12-month stretch.
View RiskTNON must sustain revenue growth near $1.47 million quarterly to justify its price. Recent revenue was $1.3 million, falling short of the target. The company reported 127% year-over-year revenue growth in Q2 2026, but missed earnings expectations by $3.95. It trades at a valuation below typical for its sector. This reflects skepticism about its ability to maintain growth. A 60% probability of missing outlooks adds to the risk. The thesis has broken due to the primary pillar failing to meet revenue targets.
Trailing returns as of 2026-09-04. TNON is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering TNON (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare TNON with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TNON Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put TNON next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Capital raising through securities offerings
Capital raised supports financial growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Address Nasdaq listing compliance issues
Regaining compliance supports regulatory objectives and market confidence.
Advances: Drive revenue growth and improve financial results
Record revenue growth aligns with management's growth objectives.
Advances: Expand training activities and commercial build-out
FDA clearance supports revenue growth and commercial expansion.
Threatens: Drive revenue growth and improve financial results
Earnings miss indicates challenges in driving revenue growth.
Advances: Secure additional financing
Secures financing to support growth initiatives.